Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
26-07-23	€1.148	+4.27%
26-07-22	€1.101	-8.10%
26-07-21	€1.198	-4.16%
26-07-20	€1.250	-8.69%
26-07-17	€1.369	+1.26%

Delayed Quote Börse Stuttgart

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.270USD

Average target price

4.000USD

Spread / Average Target

+214.96%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Tradegate Other stock markets 09:30:25 2026-07-23 EDT			5-day change	1st Jan Change
1.099 ^EUR	-0.18%		-24.28%	-42.24%

07-15	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion	DJ
07-14	Innovent Biologics, Inc. and Spero Therapeutics, Inc. Announce Exclusive License Agreement for IBI355, Phase 2-Ready Third-Generation Anti-CD40L Antibody	CI

Market Cap	73.53M 64.43M 59.81M 54.96M 104M 7.1B 105M 713M 279M 3.47B 276M 270M 11.99B	P/E 2024	-0.81x	P/E 2025	15.5x
Enterprise Value	73.53M 64.43M 59.81M 54.96M 104M 7.1B 105M 713M 279M 3.47B 276M 270M 11.99B	EV / Sales 2024	1,170,430x	EV / Sales 2025	-
Free-Float	77.54%	Yield 2024 *	-	Yield 2025	-

07-15	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion	DJ
07-14	Innovent Biologics, Inc. and Spero Therapeutics, Inc. Announce Exclusive License Agreement for IBI355, Phase 2-Ready Third-Generation Anti-CD40L Antibody	CI
07-14	Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing	MT
07-14	Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion	RE
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Growth Benchmark	CI
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Index	CI
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Index	CI
06-28	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index	CI
06-17	GSK says US FDA approves urinary tract infection treatment Utebzi	AN
06-17	GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections	CI
06-17	GSK Secures US FDA Nod for Complicated Urinary Tract Infection Antibiotic	MT
06-17	GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections	MT
06-17	GSK, Spero Therapeutics Gain U.S. Approval for Utebzi	DJ

25-10-21	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
24-12-20	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
24-11-18	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
24-08-06	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
23-08-14	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT

Spero Therapeutics, Inc. Stock Börse Stuttgart

Stocks

2HA

US84833T1034

Biotechnology & Medical Research

Valuation: Spero Therapeutics, Inc.

Chart: Spero Therapeutics, Inc.

Latest news : Spero Therapeutics, Inc.

Last Transcript: Spero Therapeutics, Inc.

Analysts' recommendations: Spero Therapeutics, Inc.

Press Releases: Spero Therapeutics, Inc.

News in other languages: Spero Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Spero Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-14	Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties	AQ
07-14	Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody	AQ
05-13	Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update	AQ
05-05	Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026	AQ
03-26	Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update	AQ

06-18	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
06-18	Star Warsh
06-18	MORNING BRIEFING - Deutschland/Europa -2-
06-17	GSK und Spero Therapeutics erhalten US-Zulassung für Utebzi
25-10-21	GSK et Spero publient des résultats positifs sur un antibiotique expérimental

1 week	-24.28%
Current month	-42.72%
1 month	-42.45%
3 months	-54.35%
6 months	-46.55%
Current year	-42.24%

Manager	Title	Age	Since
Esther Rajavelu CEO	Chief Executive Officer	47	2025-01-09
Timothy Keutzer COO	Chief Operating Officer	58	2023-01-31
Shai Biran IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Milind Deshpande CHM	Chairman	69	2013-12-31
Patrick Volkert Vink BRD	Director/Board Member	62	2015-08-31
Frank Thomas CHM	Chairman	56	2025-01-09

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPERO THERAPEUTICS, INC.	-0.18%	-24.28%	-45.50%	-14.72%	73.53M
WUXI APPTEC CO., LTD.	-0.43%	-4.26%	+52.09%	+85.69%	55.27B
ARGENX SE	-1.00%	+1.85%	+56.42%	+59.55%	54.15B
INSMED INCORPORATED	-0.88%	-2.89%	+3.61%	+405.88%	23.11B
BIONTECH SE	-1.46%	-0.17%	-17.60%	-15.43%	23.22B
WUXI BIOLOGICS (CAYMAN) INC.	+1.03%	-0.20%	+36.49%	-3.23%	20.33B
GENMAB A/S	-2.39%	-0.90%	+29.25%	-30.46%	17.91B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.87%	-0.19%	+39.07%	+553.51%	15.76B
PHARMAESSENTIA CORPORATION	+0.43%	-10.61%	+175.63%	+299.61%	15B
EXELIXIS, INC.	-1.16%	-1.03%	+23.63%	+179.23%	13.82B
Average	-0.23%	-1.65%	+35.31%	+151.96%	26.51B
Weighted average by Cap.	-0.14%	-1.05%	+43.78%	+134.37%

	2024	2025
Net sales	47.98M 42.04M 39.03M 35.86M 67.57M 4.63B 68.57M 465M 182M 2.27B 180M 176M 7.83B	66.8M 58.53M 54.34M 49.93M 94.09M 6.45B 95.47M 647M 253M 3.15B 251M 245M 10.9B
Net income	-68.57M -60.08M -55.77M -51.25M -96.57M -6.62B -97.99M -664M -260M -3.24B -257M -252M -11.18B	8.57M 7.51M 6.97M 6.41M 12.07M 827M 12.25M 83.06M 32.51M 405M 32.18M 31.48M 1.4B
Net Debt	-	-

1 week	1.08	1.45
1 month	1.08	2.02
3 years	0.49	2.6
5 years	0.49	16.6